ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 34820552

Resetting amino acid metabolism of cancer cells by ATB0,+-targeted nanoparticles for enhanced anticancer therapy.

Kou L and 10 others. Bioact Mater, 2022. Cited by 32 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Resetting amino acid metabolism of cancer cells by ATB0,+-targeted nanoparticles for enhanced anticancer therapy. Papers, record 34820552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34820552

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Resetting amino acid metabolism of cancer cells by ATB0,+-targeted nanoparticles for enhanced anticancer therapy.
PubMed
Journal
Bioact Mater
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
1.75
iCite
Revised in PubMed
2021-11-26
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kou LLongfa
2Jiang XXinyu
3Tang YYingying
4Xia XXing
5Li YYingtao
6Cai AAimin
7Zheng HHailun
8Zhang HHailin
9Ganapathy VVadivel
10Yao QQing

1 to 10 of 11Source PubMed

See all 11 authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116,452,222Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.Cancer Res2006https://conductscience.org/library/papers/16452222PubMed
223,402,769Nutrient transporters: the Achilles' heel of anabolism.Trends Endocrinol Metab2013https://conductscience.org/library/papers/23402769PubMed
331,277,692Targeting mTOR for cancer therapy.J Hematol Oncol2019https://conductscience.org/library/papers/31277692PubMed
431,100,853The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer.Int J Mol Sci2019https://conductscience.org/library/papers/31100853PubMed
521,771,784SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer.J Biol Chem2011https://conductscience.org/library/papers/21771784PubMed
619,203,585Bidirectional transport of amino acids regulates mTOR and autophagy.Cell2009https://conductscience.org/library/papers/19203585PubMed
724,823,347Nanoparticle exposure in animals can be visualized in the skin and analysed via skin biopsy.Nat Commun2014https://conductscience.org/library/papers/24823347PubMed
826,774,224Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination.J Control Release2016https://conductscience.org/library/papers/26774224PubMed
931,676,386Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB0,+ for efficient tumor therapy.J Control Release2019https://conductscience.org/library/papers/31676386PubMed
1031,819,199Metabolism and cancer: the future is now.Br J Cancer2020https://conductscience.org/library/papers/31819199PubMed

1 to 10 of 35

See all 35 references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
42,953,814A Narrative Review of Nanomedicine in Cancer Therapy: Modulating Metabolic Reprogramming to Enhance Immunotherapy.Int J Nanomedicine2026https://conductscience.org/library/papers/42953814PubMed
42,776,395Emerging roles of SLC6A14 in digestive system diseases: from amino acid transport to therapeutic targeting.Mol Biol Rep2026https://conductscience.org/library/papers/42776395PubMed
42,694,573Beyond Glucose and Lipids: The Pivotal Role of Amino Acid Reprogramming in Shaping the Tumor Microenvironment and Guiding the Development of Novel Therapeutics.Int J Med Sci2026https://conductscience.org/library/papers/42694573PubMed
42,434,841Carrier-Free Nanoparticles Enhance Photothermal-Immune Therapy via Metabolic Reprogramming in Triple-Negative Breast Cancer.Adv Healthc Mater2026https://conductscience.org/library/papers/42434841PubMed
41,451,409Stereoselective design of amino acid bioconjugates: targeting strategies and physicochemical optimization.RSC Med Chem2026https://conductscience.org/library/papers/41451409PubMed
41,215,766In situ forming hydrogels for colorectal cancer therapy.Mater Today Bio2025https://conductscience.org/library/papers/41215766PubMed
40,959,206Natural Killer Cell-Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications.MedComm (2020)2025https://conductscience.org/library/papers/40959206PubMed
40,940,612Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40940612PubMed
40,625,405Dynamic crosstalk between amino acid metabolism and cancer drug efficacy: From mechanisms to therapeutic opportunities.iScience2025https://conductscience.org/library/papers/40625405PubMed
39,420,366Stable triangle: nanomedicine-based synergistic application of phototherapy and immunotherapy for tumor treatment.J Nanobiotechnology2024https://conductscience.org/library/papers/39420366PubMed

1 to 10 of 20

See all 20 cited by

Genes14

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
BAX581PubTator's text mininghttps://conductscience.org/library/genes/581NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
HIF1A3,091PubTator's text mininghttps://conductscience.org/library/genes/3091NCBI Gene
HPRT13,251PubTator's text mininghttps://conductscience.org/library/genes/3251NCBI Gene
MTOR2,475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
POTEF728,378PubTator's text mininghttps://conductscience.org/library/genes/728378NCBI Gene
SLC1A56,510PubTator's text mininghttps://conductscience.org/library/genes/6510NCBI Gene

1 to 10 of 14

See all 14 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34820552

GET https://conductscience.org/api/papers/v1/34820552/references?page=2

API referenceFor AI assistants